Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma.

Mol Biol Rep 2018 Dec 19;45(6):2615-2623. Epub 2018 Oct 19.

Department of Pathology, Shihezi University School of Medicine, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, 832003, Xinjiang, China.

Hsa-MicroRNA-124a-3p (hsa-miR-124-3p) is involved in tumor progression in certain malignant tumors. However, its function and clinical implication in hepatocellular carcinoma (HCC) have not yet been illustrated. In this study, we explored the expression and prognostic value of hsa-miR-124-3p in patients with HCC. Hsa-miR-124-3p expression in HCC was analyzed in silico, which was subsequently confirmed by quantitative PCR in 155 HCC biopsy samples. Overall survival (OS) and disease-free survival in HCC patients was evaluated by Kaplan-Meier survival analysis, and univariate and multivariate Cox proportional hazard models were used. The in silico results demonstrated that hsa-miR-124-3p was reduced in cell lines and tissues of HCC, and hsa-miR-124-3p expression was lower in HCC tumor samples than in normal liver tissues. Moreover, a decrease in hsa-miR-124-3p expression was closely correlated with tumor diameter (≥ 5 cm) and number of lesions (multiple). Lower hsa-miR-124-3p expression was shown to be correlated with a shorter OS and poor prognosis in HCC. Our findings demonstrate that hsa-miR-124-3p might be a potential target for the diagnosis and prognosis of HCC.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-018-4431-1DOI Listing
December 2018
4 Reads

Publication Analysis

Top Keywords

hsa-mir-124-3p expression
16
hcc
9
hepatocellular carcinoma
8
hsa-mir-124-3p
8
prognosis hcc
8
hcc hsa-mir-124-3p
8
expression
5
cox proportional
4
multivariate cox
4
proportional hazard
4
models silico
4
reduced cell
4
cell lines
4
lines tissues
4
hsa-mir-124-3p reduced
4
demonstrated hsa-mir-124-3p
4
univariate multivariate
4
silico demonstrated
4
hazard models
4
survival analysis
4

References

(Supplied by CrossRef)

Y Wang et al.
J Cell Mol Med 2012

SD Wu et al.
Cancer Treat Rev 2012

LL Liu et al.
Stem Cells Dev 2011

Z Liang et al.
Oncotarget 2017

LK Hou et al.
PLoS ONE 2017

Q Huang et al.
Jpn J Clin Oncol 2017

P Luo et al.
Mol Med Rep 2017

H Lv et al.
Cancer Lett 2018

H Yang et al.
Oncol Lett 2018

YS Ma et al.
Oncotarget 2017

RT Xie et al.
Oncol Lett 2018

Similar Publications